NLE Psychiatric Disorders — Substance Use and Addictive DisordersStudy Notes

Before studying specific substances, it is essential to distinguish four frequently confused terms that form the foundation of understanding substance use disorders: **Tolerance** is a *physiologic* adaptation where the body requires increasingly larger doses of a substance to achieve the same effect. At the cellular level, neurons adjust their receptor sensitivity or metabolism to compensate for the drug's presence. Tolerance does not equal addiction and can occur with appropriately prescribed medications (e.g., a patient on long-term opioid pain management may become tolerant). It reflects neuroadaptation, not behavioral compulsion. **Physical Dependence** occurs when the body has adapted so completely to the presence of a substance that its removal triggers a withdrawal syndrome—a cluster of predictable physiologic and psychological symptoms. Like tolerance, physical dependence can develop with prescribed medications and is distinct from addiction. It is an automatic physiologic response, not a moral failing or character defect. **Addiction** (also called *substance use disorder*) is a behavioral and psychological pattern characterized by: (1) loss of control over use, (2) compulsive use despite significant harm (medical, legal, social, occupational), (3) persistent craving, and (4) continued use despite wanting to stop. Addiction is the behavioral and psychological component—it is what distinguishes someone who takes opioids for legitimate pain relief from someone who compulsively seeks opioids despite negative consequences. **Withdrawal** is the syndrome of signs and symptoms that emerge when a central nervous system (CNS) depressant (alcohol, benzodiazepines, barbiturates, opioids) or stimulant is reduced or discontinued after chronic use. The specific syndrome varies by substance, but the underlying principle is the same: the body has adapted to the substance's presence, and its sudden absence causes a rebound effect. **Intoxication** is the reversible, substance-specific constellation of behavioral and physiologic changes produced by recent exposure to a psychoactive substance. For alcohol, intoxication means slurred speech and incoordination; for stimulants, it means dilated pupils and hypertension. **Codependency** refers to a dysfunctional family or relationship dynamic in which loved ones (family members, partners) unconsciously enable or perpetuate the addicted person's substance use through actions such as covering up consequences, making excuses, or taking on the person's responsibilities. Codependents often neglect their own needs and emotional well-being. **Dual Diagnosis** (also called *comorbidity*) describes a person with co-occurring substance use disorder and another psychiatric illness (e.g., major depressive disorder, schizophrenia, bipolar disorder, anxiety disorder, or PTSD). The two conditions interact—for example, someone may use alcohol to self-medicate depression, or stimulant use may precipitate psychosis in a predisposed individual. Treatment must address both conditions concurrently.

Alcohol is a **central nervous system (CNS) depressant**. It acts on multiple neurotransmitter systems—primarily enhancing inhibitory GABA signaling and suppressing excitatory glutamate—resulting in depressed CNS activity. Chronic use causes neuroadaptation: the brain upregulates excitatory systems to compensate for alcohol's constant depression, a state called *neuroplasticity*. ### Acute Intoxication Alcohol intoxication produces a dose-dependent spectrum of CNS depression: mild intoxication (low blood alcohol concentration, BAC ~0.05–0.10%) causes impaired judgment, slight incoordination, and mood lability; moderate intoxication (BAC 0.10–0.25%) produces slurred speech, ataxia (unsteady gait), nystagmus (involuntary eye movements), and emotional instability; severe intoxication (BAC >0.25%) causes significant respiratory depression, stupor, coma, and risk of death. The **priority danger in alcohol overdose is respiratory depression and aspiration**—the airway must be protected. ### The Alcohol Withdrawal Syndrome: Timeline and Severity Because alcohol depresses the CNS, its removal produces a **rebound of CNS excitation**. Withdrawal is a potentially *life-threatening medical emergency* if untreated. The timeline is critical for NLE preparation and clinical practice: **6–12 hours after the last drink: Early Withdrawal** - Tremors ("the shakes," especially noticeable in the hands) - Anxiety and nervousness - Nausea and vomiting - Insomnia and nightmares - Sweating (diaphoresis) - Elevated heart rate (tachycardia) and blood pressure (hypertension) - Headache - These symptoms reflect emerging CNS excitation but consciousness and orientation remain intact. **12–24 hours: Alcoholic Hallucinosis** - Visual, tactile, or auditory hallucinations may appear (usually visual) - **Critically: The sensorium remains relatively clear**—the patient knows these hallucinations are not real (i.e., **hallucinations WITH insight**) - Autonomic symptoms intensify - This is still withdrawal, not delirium tremens **24–48 hours: Withdrawal Seizures ("Rum Fits")** - Generalized tonic-clonic seizures, typically brief and multiple - Often occur without warning - Represent severe CNS hyperexcitability - Are a medical emergency; status epilepticus is possible **48–72 hours (Peak): Delirium Tremens (DTs)** - The most severe form of alcohol withdrawal - Characterized by a triad: 1. **Severe autonomic hyperactivity**: marked tachycardia (heart rate often >120 bpm), severe hypertension, hyperthermia (fever, sometimes >40°C), and profuse diaphoresis 2. **Profound disorientation and confusion**: the patient is completely confused about time, place, and person 3. **Vivid, frightening hallucinations**: often visual (e.g., seeing insects, snakes, or threatening figures) or tactile (e.g., feeling bugs crawling on the skin—"formication"); these are hallucinations WITHOUT insight (the patient believes they are real) - Agitation, tremors, and a sense of impending doom are prominent - **Mortality without treatment is 5–15%** due to seizures, dysrhythmias, hyperthermia, or cardiovascular collapse - DTs constitute a **psychiatric emergency** The key distinction: **alcoholic hallucinosis** (at 12–24 hours) has a clear sensorium; **delirium tremens** (at 48–72 hours) has profound confusion and disorientation. ### Nursing Management of Acute Alcohol Withdrawal and Delirium Tremens Using the nursing process and NANDA terminology: **Assessment:** - Obtain a detailed history of alcohol use: quantity, frequency, last drink, prior withdrawals, and prior seizures or DTs - Assess vital signs (baseline and frequency) - Perform a mental status examination: orientation to person/place/time, hallucinations, and suicidality - Assess for signs of malnutrition, liver disease, and infection **NANDA Nursing Diagnoses** (examples): - Risk for injury related to tremors, seizures, or confusion - Risk for seizures related to CNS hyperexcitability - Disturbed thought processes related to hallucinations and disorientation - Anxiety related to withdrawal symptoms - Deficient fluid volume related to diaphoresis and vomiting - Imbalanced nutrition: less than body requirements related to poor intake and chronic use **Priority Nursing Interventions** (Maslow's hierarchy: safety is first): 1. **Maintain a safe environment**: - Place the patient in a quiet, well-lit, private room (reduces misperceptions, shadows, and stimuli that trigger or intensify hallucinations) - Institute **fall precautions**: raise side rails, orient the patient frequently, assist with ambulation - Institute **seizure precautions**: keep a padded tongue blade and suction at the bedside, have IV access, keep the bed low - Assign a staff member to stay with the patient if severely agitated or hallucinating - Remove any objects that could be used for self-harm - Avoid restraints unless absolutely necessary (they increase agitation); instead, use constant observation 2. **Monitor vital signs frequently**: - Autonomic instability (severe hypertension, tachycardia, hyperthermia) can lead to dysrhythmias, myocardial infarction, or stroke - Check vitals at least every 1–2 hours during acute withdrawal, more frequently during DTs - Report abnormalities (especially hyperthermia >40°C or severe hypertension) immediately 3. **Administer pharmacologic therapy as ordered** (see pharmacology section below) 4. **Maintain fluid and electrolyte balance**: - Establish IV access; administer IV fluids (usually normal saline or dextrose with normal saline) - Monitor urine output (dehydration from diaphoresis and poor intake is common) - Monitor electrolytes, particularly magnesium, phosphate, and potassium (hypomagnesemia and hypophosphatemia are common and can precipitate seizures and dysrhythmias) - **Never give glucose without thiamine**—see section below 5. **Provide reorientation and reassurance**: - Speak calmly and clearly - Reorient the patient frequently: "You are in the hospital. Today is Tuesday. You are safe." - Do not argue about the reality of hallucinations; instead, offer reassurance: "I know you are frightened. I am here with you. You are safe." - Avoid sudden movements or loud noises 6. **Nutritional support**: - Once the patient can tolerate oral intake, provide a diet rich in vitamins and minerals - Administer **thiamine (vitamin B1), folic acid, and multivitamins** as ordered (discussed below) 7. **Documentation and communication**: - Document the time of last drink, onset and progression of symptoms, vital signs, behavior, medications given, and response - Communicate with the healthcare team about the patient's status and any changes ### Pharmacology of Alcohol Withdrawal **Benzodiazepines: First-Line Treatment** **Benzodiazepines are the gold standard, drug-of-choice treatment** for alcohol withdrawal and delirium tremens. They work by enhancing GABA signaling, effectively replacing the CNS-depressant effect that alcohol provided. Common agents include: - **Diazepam** (long-acting; useful for longer coverage but contraindicated in liver disease) - **Lorazepam** (shorter-acting; preferred in liver disease because it is metabolized by glucuronidation, not hepatic oxidation) - **Chlordiazepoxide** (intermediate-acting; commonly used) **Dosing approaches:** 1. **Fixed schedule**: a predetermined dose at regular intervals (e.g., lorazepam 2 mg every 6 hours for 5 days) 2. **Symptom-triggered regimen**: medication is administered based on a validated withdrawal assessment scale (CIWA-Ar, discussed below), titrated to patient need—this reduces total benzodiazepine exposure and is increasingly preferred **Nursing considerations:** - Assess the patient's baseline respiratory status before administration; do not administer if respiratory depression is present - Monitor for oversedation and respiratory depression; have emergency equipment and naloxone available - Establish IV access; benzodiazepines can be given IV for faster onset in severe withdrawal or DTs - Taper benzodiazepines gradually over days; **abrupt discontinuation can precipitate withdrawal from the benzodiazepine itself** - Avoid abrupt cessation in any CNS depressant—always taper - Monitor for signs of dependence or abuse in patients with a history of substance use disorder **Thiamine (Vitamin B1) and the Prevention of Wernicke's Encephalopathy** Chronic alcohol use depletes **thiamine (vitamin B1)** stores. Thiamine is essential for carbohydrate metabolism and neuronal function. When glucose is administered to a thiamine-deficient patient, the glucose consumption further depletes remaining thiamine, potentially triggering or worsening **Wernicke's encephalopathy**—a medical emergency. **Golden rule: Always give thiamine BEFORE or SIMULTANEOUSLY with glucose in a patient with alcohol use disorder.** - **Dosage**: Typically 100 mg IM or IV, often given daily for 3–5 days, then oral 100 mg daily - Administer **before** any IV dextrose - If the patient cannot tolerate oral intake, give IM or IV thiamine - Also administer **folic acid** (1 mg daily) and a **multivitamin** to address other nutritional deficiencies **Magnesium Replacement** - Chronic alcohol use and diarrhea/vomiting during withdrawal cause **hypomagnesemia** (low magnesium) - Hypomagnesemia lowers the seizure threshold and increases cardiac dysrhythmias - Magnesium sulfate (or MgSO₄) is administered IM or IV to replace stores and reduce seizure risk - Nursing consideration: IM magnesium is painful; IV administration requires careful monitoring for hypermagnesemia **Other supportive medications:** - **Clonidine** (an alpha-2 adrenergic agonist): helps control autonomic symptoms (hypertension, tachycardia, tremor) but is not a substitute for benzodiazepines - **Carbamazepine** or **phenytoin**: sometimes used as adjunctive agents for seizure prevention, though benzodiazepines are primary ### The CIWA-Ar (Clinical Institute Withdrawal Assessment for Alcohol, Revised) The **CIWA-Ar** is a validated, 10-item scale that quantifies the severity of alcohol withdrawal. It is used to guide **symptom-triggered** benzodiazepine dosing—rather than giving a fixed dose on a fixed schedule, the nurse assesses the patient using the CIWA-Ar, and the score determines whether and how much medication is given. **CIWA-Ar items:** 1. Nausea and vomiting 2. Tremor (visually rated and palpated) 3. Paroxysmal sweats 4. Anxiety 5. Agitation 6. Tactile disturbances (e.g., itching, tingling, feeling of "bugs on skin") 7. Auditory disturbances 8. Visual disturbances 9. Headache 10. Orientation and clouding of sensorium **Scoring:** - Total score ranges from 0 to 67 - **Score <10**: minimal withdrawal; typically no medication needed - **Score 10–20**: mild to moderate withdrawal; benzodiazepine given - **Score >20**: severe withdrawal; benzodiazepine given; may require hospitalization or ICU monitoring **Advantages of symptom-triggered dosing:** - Reduces total benzodiazepine exposure (lower risk of dependence on benzodiazepines) - Individualizes treatment to patient need - Reduces overmedicating mild withdrawals and undermedicating severe ones - Requires trained nursing assessment and frequent patient contact **Clinical example**: A patient is admitted with last drink 12 hours ago. CIWA-Ar score is 18 (tremor, anxiety, diaphoresis, mild nausea). The standing order might be "Lorazepam 1–2 mg IV/PO for CIWA score >10." The nurse gives lorazepam 2 mg. Four hours later, the CIWA score is 5 (tremor resolving, minimal anxiety); no medication is given. This individualized approach is superior to simply giving lorazepam 2 mg every 6 hours regardless of need. ### Wernicke-Korsakoff Syndrome: A Complication of Chronic Alcohol Use Chronic, heavy alcohol use causes persistent **thiamine (vitamin B1) deficiency**, leading to a two-part syndrome: **Wernicke's Encephalopathy** (Acute, Reversible): - A **medical and psychiatric emergency** - Results from thiamine deficiency and impaired glucose metabolism in the brain - **Classic triad**: 1. **Confusion and disorientation** (altered mental status) 2. **Ophthalmoplegia and nystagmus** (abnormal eye movements; patients may have trouble focusing, diplopia, or restricted eye movements) 3. **Ataxia** (loss of coordination; gait disturbance, inability to walk a straight line) - Other signs: hypothermia, hypotension, coma - **Treatment: Immediate IV thiamine** (typically 100 mg IV/IM) can reverse symptoms if given early; delayed treatment may result in progression to Korsakoff's - **Key nursing action**: Recognize the triad and advocate for **urgent thiamine administration** **Korsakoff's Psychosis (Chronic, Largely Irreversible):** - Results from permanent neuronal damage (particularly to the mammillary bodies and medial thalamus) from prolonged thiamine deficiency - **Dominant feature: Profound short-term (anterograde) memory loss**—the patient cannot form new memories - **Confabulation**: the patient unconsciously fills memory gaps with fabricated information (not deliberate lying; the patient genuinely believes the false memories) - Patients may not recognize family members or understand why they are in the hospital - Long-term (retrograde) memory may also be impaired - **Largely irreversible**, though some patients show modest improvement with aggressive thiamine and supportive care - Nursing considerations: provide a structured, safe environment; reorient frequently; accept confabulation without confrontation; involve family in understanding the patient's limitations **The critical teaching point for NLE and clinical practice: Always give thiamine BEFORE glucose in any patient with suspected alcohol use disorder, malnutrition, or altered mental status.** This single action can prevent a medical emergency.

**Disulfiram** (Antabuse) is a medication used to support abstinence in patients with alcohol use disorder by creating a strong negative consequence if alcohol is consumed. It is NOT a treatment for withdrawal or acute intoxication; rather, it is a **maintenance medication** for motivated patients committed to abstinence. ### Mechanism of Action Disulfiram blocks the enzyme **aldehyde dehydrogenase**, which normally metabolizes acetaldehyde (an intermediate metabolite of alcohol). When a person taking disulfiram drinks alcohol, acetaldehyde accumulates to toxic levels, triggering the **disulfiram-alcohol reaction** (also called the flushing reaction or Antabuse reaction): ### The Disulfiram-Alcohol Reaction If a patient on disulfiram consumes alcohol, the following severe reaction occurs within 5–30 minutes: - **Facial flushing** (intense redness and warmth of the face and chest) - **Throbbing headache** (often severe) - **Nausea and vomiting** (can be projectile) - **Chest pain and dyspnea** (chest tightness and shortness of breath) - **Tachycardia and palpitations** (heart racing) - **Hypotension** (sudden drop in blood pressure, dizziness, syncope) - **Diaphoresis** (profuse sweating) - In severe cases: **cardiovascular collapse, arrhythmias, myocardial infarction, or death** The reaction is extremely unpleasant, reinforcing the decision not to drink. The effect lasts 30 minutes to several hours and generally resolves as acetaldehyde is metabolized. ### Nursing Considerations and Patient Teaching **Before starting disulfiram:** - Ensure the patient is **fully abstinent from alcohol** (ideally for at least 12–24 hours before the first dose) - Assess **motivation and informed consent**; the patient must genuinely want to be on the medication and understand the consequences - Screen for psychiatric comorbidities, especially suicidal ideation (some patients taking disulfiram may deliberately drink to provoke a reaction as a form of self-harm) - Obtain a baseline physical examination and liver function tests (AST, ALT, bilirubin), as disulfiram itself can be hepatotoxic - Educate the patient comprehensively about hidden alcohol sources **Patient teaching: Hidden sources of alcohol to avoid** The patient must understand that disulfiram reacts with ANY source of alcohol, including: - **Obvious sources**: beer, wine, spirits, liqueurs - **Mouthwash and dental products**: many contain 15–27% alcohol; the patient must use alcohol-free mouthwash - **Cough syrups and cold remedies**: many OTC formulations contain 5–10% alcohol - **Aftershave, cologne, and perfumes**: spray these on clothing, not skin; or use alcohol-free alternatives - **Cooking ingredients**: vanilla extract (35% alcohol), wine used in cooking (some alcohol remains), wine vinegar - **Sauces and condiments**: some hot sauces, teriyaki sauce, soy sauce - **Foods**: some desserts made with alcohol (tiramisu, fruit cakes with brandy) - **Other products**: some deodorants, antiseptic products, and even some nail polish removers **Duration of effect:** Disulfiram is slowly eliminated and can remain in the body for **1–2 weeks** after the last dose. A patient could still experience a reaction even days after stopping the medication if they drink alcohol. **Nursing monitoring:** - Monitor liver function tests regularly (baseline and periodically) - Assess adherence; check if the patient is actually taking the medication - Explore motivation; if the patient "forgets" to take it, motivation may be wavering - Watch for signs of depression or suicidal ideation (some patients may use the medication to self-sabotage) - Reinforce the importance of attending **Alcoholics Anonymous (AA)** or other support groups; disulfiram alone does not provide the counseling and peer support necessary for long-term recovery **Contraindications and cautions:** - **Active drinking or recent alcohol use**: do not give disulfiram; ensure abstinence first - **Severe cardiac disease or coronary artery disease**: the cardiovascular stress of a disulfiram reaction is dangerous - **Psychosis or severe depression with suicidal ideation**: risk of deliberate self-harm via intentional alcohol consumption - **Pregnancy**: disulfiram is teratogenic - **Medications that interact**: some antifungals (metronidazole, ketoconazole) and other drugs can also inhibit aldehyde dehydrogenase and cause reactions ### Alternative Medications: Naltrexone and Acamprosate While disulfiram creates a punitive consequence, two other medications work differently to support abstinence: **Naltrexone**: An opioid antagonist that blocks opioid receptors in the brain. In the context of alcohol use disorder, it is thought to reduce the **rewarding effect** of alcohol (blunting cravings). It does NOT cause a reaction if alcohol is consumed; it simply makes drinking less pleasurable. Naltrexone is available as daily PO or as a monthly IM injection (Vivitrol). **Acamprosate**: Believed to restore balance in the brain's glutamate and GABA systems disrupted by chronic alcohol use. It reduces cravings and protects against relapse but, like naltrexone, does NOT cause a reaction with alcohol. It is given three times daily and is safe even if the patient drinks (no severe interaction). Both are adjuncts to counseling and behavioral therapy, not replacements.

Opioids—including heroin, morphine, codeine, oxycodone, and other prescription analgesics—are **CNS and respiratory depressants**. They bind to opioid receptors in the brain and spinal cord, producing analgesia, euphoria, and respiratory depression. Opioid use disorder is a major public health crisis globally and is increasingly prevalent in the Philippines, particularly with the misuse of prescription painkillers and illicit opioids. ### Acute Opioid Intoxication and Overdose Opioid intoxication (and overdose) presents a characteristic triad—the **toxic triad of opioid overdose**: 1. **Pinpoint (constricted) pupils** (miosis): pupils are typically 1–2 mm in diameter, responsive only minimally to light 2. **Respiratory depression**: slow, shallow breathing (bradypnea), decreased oxygen saturation, potential respiratory arrest 3. **Decreased level of consciousness**: sedation, stupor, or coma **The life-threatening danger is respiratory depression leading to hypoxemia, hypercapnia, and respiratory arrest.** Additionally, aspiration is a risk if the patient is obtunded. **Associated signs and symptoms:** - **Hypothermia** (opioids suppress temperature regulation) - **Bradycardia** (opioids slow heart rate) - **Hypotension** (due to decreased sympathetic tone and direct vasodilation) - **Pulmonary edema** (noncardiogenic; opioids increase pulmonary capillary permeability, and hypoxemia worsens this) - **Cyanosis** (bluish discoloration of lips, fingertips) - **Cold, clammy skin** **Emergency management (before pharmacologic therapy):** - **Ensure airway, breathing, circulation (ABCs)**; position the patient supine with head turned to the side to prevent aspiration - **Establish IV access** immediately - **Obtain baseline oxygen saturation and blood gases**; provide supplemental oxygen (aim for O₂ sat >90%) - **Prepare for intubation** if respiratory depression is severe - **Keep the patient warm** (use blankets, warm IV fluids) to combat hypothermia - **Place on continuous cardiac monitoring** (dysrhythmias are possible, especially with heroin laced with other substances) - **Send blood and urine for toxicology** (to confirm opioid presence and rule out other drugs) ### Naloxone: The Opioid Antagonist and Reversal Agent **Naloxone** (Narcan) is a **competitive opioid antagonist**. It binds to opioid receptors with high affinity, displacing opioids and rapidly reversing their effects. **Mechanism:** - Naloxone competitively binds to mu (μ), kappa (κ), and delta (δ) opioid receptors - It has no intrinsic opioid activity (is not an agonist); it simply blocks the opioid's effect - Onset is **rapid**: IV naloxone works within 1–2 minutes; IM within 5–10 minutes; intranasal within 2–3 minutes **Dosing and routes:** - **IV**: 0.4–2 mg, may repeat every 2–3 minutes up to 10 mg total - **IM/SC**: 0.4–2 mg, may repeat; slower onset than IV - **Intranasal**: 4 mg (one spray in one nostril); rapid onset, non-invasive, increasingly used in community settings - **Auto-injector (Evzio)**: pre-filled 0.4 mg auto-injector for lay public/EMS **Nursing considerations:** 1. **Establish IV access first** if possible; IV is the fastest route in hospital settings 2. **Draw blood for toxicology and baseline labs** before or immediately after naloxone administration 3. **Administer naloxone** as ordered; observe for response (pupils dilate, respiratory rate increases, level of consciousness improves) 4. **DO NOT give naloxone if opioid use is uncertain** (e.g., respiratory depression may be from another cause); however, **naloxone is safe if given for non-opioid causes—it simply will have no effect** 5. **Monitor continuously for RE-SEDATION**: naloxone is **short-acting** (half-life 30–81 minutes, depending on the route and formulation). Many opioids (especially long-acting ones like methadone) have a longer duration, so the patient can become re-sedated as naloxone wears off while opioid remains in the system. **Repeat naloxone doses every 2–3 minutes as needed, or consider a naloxone infusion** 6. **Be prepared for acute withdrawal**: naloxone precipitates acute opioid withdrawal, which, while not life-threatening, is intensely uncomfortable (see section below) and can make the patient very agitated. Have additional staff available and be prepared to reassure the patient 7. **Never leave the patient unattended** after naloxone administration; continuous observation for respiratory depression is essential 8. **Do NOT allow the patient to leave the ED until cleared by a physician**; risk of re-sedation is high if the opioid dose was large or long-acting **Community naloxone:** In the Philippines and globally, naloxone auto-injectors and intranasal sprays are increasingly distributed to people with opioid use disorder and their families for emergency use. Training in recognizing overdose and administering naloxone is part of harm reduction strategies. ### Opioid Withdrawal Syndrome While opioid withdrawal is **profoundly uncomfortable and distressing**, it is **NOT life-threatening** (unlike alcohol or sedative-hypnotic withdrawal). The syndrome typically begins **6–12 hours** after the last use of short-acting opioids (e.g., heroin) or **24–48 hours** after long-acting opioids (e.g., methadone). **Signs and symptoms of opioid withdrawal:** - **Early (first 6–8 hours)**: anxiety, irritability, restlessness, yawning, lacrimation (tearing), rhinorrhea (runny nose), insomnia - **Progressive (8–24 hours)**: pupils dilate (mydriasis), gooseflesh (piloerection, "cold turkey"), muscle aches (myalgias), arthralgias (joint pain), abdominal cramping, nausea, vomiting, diarrhea - **Peak symptoms (24–72 hours)**: severe muscle aches, insomnia, intense anxiety, appetite loss, weight loss, fever, tachycardia, hypertension - **Duration**: Acute withdrawal typically peaks at 48–72 hours and gradually resolves over 5–10 days (though psychological craving persists much longer) **Why opioid withdrawal is not life-threatening:** The CNS and autonomic hyperexcitation in opioid withdrawal, while severe, does not typically reach levels that cause seizures, severe dysrhythmias, or cardiovascular collapse (unlike alcohol or benzodiazepine withdrawal). **Management of opioid withdrawal:** - **Medical management**: Opioid agonists and partial agonists (methadone, buprenorphine—see below) - **Symptomatic treatment**: - **Clonidine** (an alpha-2 adrenergic agonist) reduces autonomic symptoms (anxiety, sweating, muscle aches, tachycardia, hypertension) but does not treat craving - **NSAIDs** for muscle and joint pain - **Antidiarrheals** (loperamide) for diarrhea - **Antiemetics** (ondansetron) for nausea - **Sleep aids** (non-addictive agents such as diphenhydramine or trazodone) - **Non-pharmacologic**: supportive counseling, reassurance, hydration, nutrition, rest ### Medication-Assisted Treatment (MAT): Methadone and Buprenorphine Instead of abruptly stopping opioids and enduring withdrawal, **medication-assisted treatment (MAT)** uses opioid agonists or partial agonists to prevent withdrawal, reduce craving, and facilitate long-term recovery. **Methadone:** - A **full opioid agonist** (activates opioid receptors like heroin but with a long duration) - **Half-life**: 24–36 hours (some variability); allows once-daily dosing - **Mechanism**: Prevents withdrawal symptoms and reduces the rewarding effect of illicit opioids (because the patient is already opioid-saturated on methadone, taking heroin produces no additional euphoria) - **Typical dosing**: Starting dose is 15–20 mg PO daily; titrated upward every 3–5 days by 5–10 mg increments until the patient is stable (no withdrawal symptoms or craving, typically 60–100 mg/day, though some require higher doses) - **Administration**: Given at a methadone clinic, often daily but sometimes less frequently once stable - **Advantages**: Highly effective for preventing withdrawal and craving; long-acting; well-studied; stable patients may receive take-home bottles - **Disadvantages**: Potential for overdose (especially when combined with other CNS depressants); QT prolongation risk (requires baseline and periodic EKGs); requires clinic attendance; social stigma; slower taper if discontinuing **Buprenorphine:** - A **partial opioid agonist** (partially activates opioid receptors; less euphoric than full agonists) - Often combined with **naloxone** (marketed as Suboxone) to prevent misuse (the naloxone is inactive if the tablet is taken orally as directed but becomes active if injected, deterring IV abuse) - **Half-life**: 24–60 hours; can be given every other day or three times weekly - **Mechanism**: Prevents withdrawal and reduces craving; because it is a partial agonist, overdose risk is lower than with methadone - **Typical dosing**: Induction is 4–8 mg on day 1, then titrated upward to 12–16 mg/day, divided doses or once daily (range 8–24 mg/day) - **Administration**: Can be prescribed in office-based settings (unlike methadone), increasing accessibility and reducing stigma - **Advantages**: Lower overdose potential; less QT risk; office-based prescribing; combination with naloxone; easier taper - **Disadvantages**: Requires practitioner training and certification; may be less effective than methadone in some patients; still a controlled substance; potential for withdrawal if stopped abruptly (though less severe than full agonist withdrawal) **Nursing considerations for methadone and buprenorphine:** - Assess baseline **EKG** (especially for methadone; QT prolongation is a risk) - Monitor **liver and kidney function** (dose adjustments may be needed) - During induction, monitor for **overdose and respiratory depression** (dose is being increased); patient should not drive or operate machinery - Educate the patient: **These medications are for maintenance and are NOT recreational**; they prevent withdrawal and craving, allowing the person to regain function and pursue recovery - Warn against combining with alcohol, benzodiazepines, or other CNS depressants (overdose and respiratory depression risk is greatly increased) - Support the patient in attending counseling, group therapy, and psychosocial interventions alongside medication - Address stigma: emphasize that MAT is evidence-based treatment, not "trading one drug for another" - For patients on buprenorphine, education about not splitting tablets or injecting (the combination with naloxone deters this, but patient knowledge is important) ### Opioid Withdrawal Precipitated by Naloxone Administering naloxone to an opioid-dependent patient **precipitates acute withdrawal**—the abrupt removal of opioid effect causes immediate withdrawal symptoms (anxiety, agitation, body aches, sweating, dilated pupils, rapid heart rate). While not life-threatening, it is extremely distressing and can make the patient very angry or uncooperative. In the hospital setting, patients should be offered reassurance ('This discomfort will pass in a few hours'), observation, and symptomatic treatment (e.g., clonidine, comfort measures). Explain that precipitated withdrawal is necessary to reverse life-threatening respiratory depression. ### Psychosocial Treatment for Opioid Use Disorder MAT is highly effective but ONLY when combined with: - **Counseling and cognitive-behavioral therapy** (individual and group) - **Family involvement** (addressing codependency, rebuilding relationships) - **Peer support** (Narcotics Anonymous, SMART Recovery) - **Vocational rehabilitation** (helping the patient regain employment and social function) - **Management of comorbid mental health conditions** (depression, anxiety, PTSD often accompany opioid use disorder) - **Addressing social determinants** (housing, employment, social networks) Opioid use disorder is a chronic, relapsing condition; recovery requires long-term commitment and multiple interventions.

Stimulants are **central nervous system activators** that increase dopamine, norepinephrine, and serotonin in the brain, producing euphoria, increased alertness, and enhanced confidence. Major stimulants include cocaine, amphetamines (prescription and illicit), and methamphetamine ("shabu," "crystal meth," "speed"). In the Philippine context, methamphetamine abuse is a critical public health crisis; its use has surged over the past two decades and is a primary focus of drug enforcement and treatment efforts. ### Acute Stimulant Intoxication Stimulant intoxication produces CNS *excitation* (opposite of alcohol, opioids, and depressants). The presentation is dose-dependent: **Mild to moderate intoxication:** - **Dilated pupils** (mydriasis) - **Euphoria and heightened confidence** (especially with cocaine or methamphetamine) - **Increased alertness, hypervigilance, and paranoia** (especially as use continues or doses increase) - **Increased heart rate (tachycardia), blood pressure (hypertension), respiratory rate, and body temperature** - **Increased energy and decreased appetite** - **Tremor and restlessness** - **Sweating and piloerection** (gooseflesh) - **Insomnia** **Severe intoxication (overdose):** As intoxication worsens, the sympathetic activation becomes extreme: - **Severe hypertension and tachycardia** → risk of hypertensive emergency, myocardial infarction, stroke - **Hyperthermia** (dangerously elevated body temperature, sometimes >40°C) - **Seizures** (due to CNS hyperexcitation) - **Cardiac dysrhythmias** (including ventricular fibrillation) - **Psychosis** with paranoia, hallucinations, and delusions (especially with methamphetamine or cocaine) - **Acute coronary syndrome** (myocardial infarction, angina) - **Stroke** (hemorrhagic or ischemic) - **Cerebral edema and increased intracranial pressure** - **Rhabdomyolysis** (muscle breakdown, releasing myoglobin into blood, causing acute kidney injury) - **Pulmonary edema** - **Coma and death** **Methamphetamine-specific complications:** Methamphetamine is more neurotoxic and longer-acting than cocaine. Chronic use causes: - **"Meth mouth"**: severe tooth decay and gum disease (from dry mouth, acidic environment, poor hygiene, and direct caustic effects) - **"Meth mites"**: sensation of bugs crawling on or under the skin (formication); patients often pick at their skin, causing sores and infections - **Severe acne and skin abscesses** (from repeated injections and poor hygiene) - **Premature aging** of the face and skin - **Weight loss and malnutrition** - **Cognitive deficits and memory impairment** (from neurotoxicity) - **Persistent psychosis** even after stopping (paranoia, hallucinations, delusions) ### Management of Acute Stimulant Intoxication **General principles (supportive care; no specific antagonist like naloxone exists):** 1. **Ensure ABCs**: establish IV access, cardiac monitoring, continuous pulse oximetry, frequent vital sign monitoring 2. **Create a calm, low-stimulation environment**: - Quiet room with minimal light and noise (bright lights and loud sounds intensify agitation and paranoia) - Avoid sudden movements or loud voices - Minimal numbers of staff interacting with the patient - Reassurance and a calm demeanor from staff 3. **Monitor and manage autonomic hyperactivity**: - **Hypertension**: Typically self-limited as the drug wears off; monitor closely. If severe (SBP >180 mmHg) or accompanied by signs of end-organ damage (chest pain, dyspnea, neurologic symptoms), the physician may order **labetalol** (combined alpha and beta blocker) or **nitroprusside**. **AVOID pure beta-blockers** (e.g., propranolol) as monotherapy—unopposed alpha-adrenergic stimulation can cause paradoxical severe hypertension. **AVOID cocaine with epinephrine** in local anesthetics (increases coronary vasoconstriction and MI risk). - **Tachycardia**: Usually resolves with anxiety reduction and cooling. If severe or accompanied by dysrhythmias, monitor on cardiac monitor and follow physician orders (may include benzodiazepines or antidysrhythmics). - **Hyperthermia**: A critical emergency. Initiate **active cooling**: cool IVs, ice packs to groin and armpits (areas of high blood flow), ice water immersion if necessary. Aim to reduce temperature to <38.5°C. Severe hyperthermia can cause organ damage and death. Monitor core temperature continuously. - **Seizures**: Benzodiazepines (diazepam, lorazepam) are first-line; have them immediately available. Institute seizure precautions. 4. **Manage psychiatric symptoms**: - **Agitation**: A calm environment, reassurance, and clear communication are first-line. If necessary, benzodiazepines (lorazepam 2–4 mg IV) can be used. Avoid physical restraints unless absolutely necessary (they increase agitation). - **Psychosis and paranoia**: Reassure the patient; do not argue about the reality of hallucinations or delusions. Explain that these are effects of the drug and will resolve. If severe agitation accompanies psychosis, benzodiazepines are preferred. Antipsychotics (e.g., haloperidol) are sometimes used but are less preferred because they lower seizure threshold. - **Suicidality**: Assess suicide risk, especially during the "crash" phase (see below). Maintain close observation; place on suicide precautions if indicated. 5. **Supportive care**: - IV hydration with normal saline or dextrose-containing fluids (monitor urine output; rhabdomyolysis increases risk of acute kidney injury; maintain urine output >200 mL/hour if rhabdomyolysis suspected) - Monitor for rhabdomyolysis: check CK (creatine kinase), myoglobin, and urine myoglobin; dark or cola-colored urine suggests myoglobinuria - Monitor renal function and electrolytes - Continuous cardiac monitoring; 12-lead EKG to assess for ischemia or dysrhythmias - Chest X-ray if dyspnea or pulmonary edema suspected - CT head if altered mental status beyond expected intoxication, focal neurologic signs, or seizures 6. **Duration**: Cocaine has a short duration (15–30 min); effects typically wear off within 1–2 hours. Methamphetamine and amphetamines last longer (4–12+ hours); effects persist much longer. Monitor accordingly. ### Stimulant Withdrawal (The "Crash") When stimulant use stops, after the acute high fades, the brain's dopamine systems are depleted, producing the **withdrawal syndrome ("crash")**: **Symptoms of stimulant withdrawal ("crash"):** - **Fatigue and exhaustion** (profound; patients sleep 12–18 hours) - **Hypersomnia** (sleeping much more than usual) - **Anhedonia** (inability to feel pleasure; nothing seems enjoyable) - **Dysphoria and depressed mood** (often severe) - **Irritability and mood lability** - **Anxiety** - **Paranoia** (especially with methamphetamine; may persist beyond the acute crash) - **Intense craving** for the drug (to escape the dysphoria) - **Anergia** (lack of energy; difficulty initiating activities) - **Appetite increase** ("rebound"; patients may eat excessively) **Timeline:** - Begins within hours of the last dose (sooner with cocaine, later with methamphetamine) - Peaks within 24–72 hours - Gradually resolves over 5–10 days, though psychological craving and dysphoria can persist weeks to months **Suicide risk during the crash:** **A critical NLE point: Suicide risk is significantly elevated during the withdrawal/crash phase.** Patients are profoundly depressed, hopeless, and experiencing anhedonia; combined with access to the circumstances of their use (social networks, paraphernalia), they are at high risk. This period requires close monitoring, mental health assessment, and potentially antidepressant and anxiolytic medications. ### Management of Stimulant Withdrawal **There is no specific pharmacologic treatment for stimulant withdrawal** (unlike benzodiazepines for alcohol or methadone for opioids). Management is supportive and symptomatic: - **Reassurance and education**: Explain that the crash is temporary and will resolve; the dysphoria is a physiologic consequence of depleted dopamine, not a reflection of reality - **Sleep support**: Allow rest; provide a comfortable, safe environment. Sleep aids (diphenhydramine, trazodone, melatonin) may help if insomnia is severe, though initially patients usually sleep excessively - **Nutritional support**: Provide balanced meals; encourage hydration - **Mood support**: - SSRIs (fluoxetine, sertraline) or other antidepressants can be initiated, though their onset is 2–4 weeks; they help with dysphoria and reduce craving - Short-term benzodiazepines (lorazepam) for anxiety, used cautiously (risk of substituting benzodiazepine dependence) - **Avoid dopamine agonists** (e.g., bromocriptine, amantadine); they have not proven effective and may increase craving - **Motivational interviewing and counseling**: The crash is a critical window for intervention. Patients are often motivated to change because they are suffering. Engage them in counseling, behavioral therapy, support groups (NA, SMART Recovery), and rehabilitation - **Psychosis management**: If stimulant-induced psychosis persists beyond a few days, rule out underlying psychiatric illness and consider antipsychotic medications (risperidone, olanzapine); reassess when the patient is fully detoxified - **Suicide assessment and precautions**: Screen for suicidality; place on precautions if indicated; involve psychiatry ### Chronic Stimulant Use and Long-Term Recovery There is **no pharmacologic substitute** for stimulants like methadone is for opioids. Recovery relies entirely on: - **Behavioral and cognitive-behavioral therapy**: Addressing triggers, developing coping skills, cognitive restructuring - **Contingency management**: Rewarding abstinence (e.g., vouchers, prizes for negative urine drug screens) - **Group support**: Narcotics Anonymous, SMART Recovery, Crystal Meth Anonymous - **Treatment of comorbid conditions**: Depression, anxiety, PTSD, and other psychiatric illnesses often accompany stimulant use and must be addressed - **Social reintegration**: Employment, housing, family repair, social networks - **Avoiding high-risk situations**: People, places, and triggers associated with use Stimulant use disorders (especially methamphetamine in the Philippine context) carry significant relapse risk. Long-term follow-up, continued support, and management of underlying mental health and social factors are essential.

Sedative-hypnotics—primarily **benzodiazepines** and **barbiturates**—are CNS depressants used medically for anxiety, insomnia, seizure control, and muscle relaxation. However, they carry high abuse and dependence potential and, when misused, produce intoxication and withdrawal syndromes similar to alcohol. ### Benzodiazepines: Mechanism and Clinical Use Benzodiazepines enhance the effect of **gamma-aminobutyric acid (GABA)**, the brain's primary inhibitory neurotransmitter. They bind to GABA receptors, increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and CNS depression. **Common benzodiazepines:** - **Short-acting** (4–8 hour duration): triazolam, alprazolam, midazolam → rapid onset, rapid offset, higher abuse potential - **Intermediate-acting** (12–24 hour duration): lorazepam, oxazepam → balanced onset/offset - **Long-acting** (24+ hour duration): diazepam, chlordiazepoxide → gradual onset, prolonged effect, lower abuse potential (but accumulation with repeated dosing) **Legitimate medical uses:** - Acute anxiety - Insomnia - Seizure control (especially lorazepam and diazepam for status epilepticus) - Alcohol withdrawal (as discussed) - Muscle relaxation - Anesthesia induction **Intoxication:** Benzodiazepine intoxication mirrors alcohol: slurred speech, incoordination, ataxia, sedation, impaired judgment, emotional lability, and respiratory depression (especially with IV benzodiazepines or overdose). Overdose can be life-threatening due to respiratory depression; **flumazenil**, a benzodiazepine antagonist, can reverse it (see below). ### Barbiturates: Mechanism and Clinical Use Barbiturates (e.g., phenobarbital, pentobarbital, secobarbital) enhance GABA signaling and also directly suppress neuronal firing. Like benzodiazepines, they are CNS depressants, but they have a **much narrower margin between therapeutic and lethal dose**—overdose is more likely and more dangerous. **Clinical uses (declining due to benzodiazepine availability):** - Seizure control (phenobarbital is still used, especially in low-income countries including the Philippines) - Insomnia (less common now; benzodiazepines preferred) - Anesthesia **Intoxication and overdose:** Barbiturate intoxication resembles alcohol; overdose is particularly dangerous because there is **no specific antagonist** (unlike benzodiazepines with flumazenil). Severe overdose causes profound respiratory depression, coma, and death. Management is purely supportive: airway management, mechanical ventilation, supportive care. ### Benzodiazepine and Barbiturate Withdrawal: A Potentially Life-Threatening Emergency **Benzodiazepine and barbiturate withdrawal closely mirrors alcohol withdrawal and is equally dangerous if not managed properly.** The brain, adapted to chronic CNS depression, rebounds into a state of CNS excitation when the drug is suddenly stopped. **Withdrawal timeline** (varies by drug duration; longer-acting drugs have slower onset): - **Short-acting benzodiazepines (e.g., alprazolam)**: Onset 6–12 hours after last dose - **Long-acting benzodiazepines (e.g., diazepam)**: Onset 24–48 hours; may be delayed - **Barbiturates**: Similar timeline to benzodiazepines **Symptoms of benzodiazepine/barbiturate withdrawal** (in escalating severity): 1. **Early (first 24 hours)**: anxiety, tremors, insomnia, sweating, tachycardia, hypertension, irritability 2. **Intermediate (24–72 hours)**: agitation, hallucinations, perceptual distortions, increased autonomic hyperactivity 3. **Severe (48–96 hours)**: **seizures** (potentially status epilepticus), **delirium** (confusion, disorientation, hallucinations), severe autonomic instability (extreme hypertension, tachycardia, hyperthermia) **The critical danger: Seizures and delirium**, similar to alcohol withdrawal. **Barbiturate withdrawal is particularly dangerous because seizures are more common and more severe.** ### Management: The Golden Rule—Gradual Taper, Never Abrupt Discontinuation **CRITICAL PRINCIPLE: Never abruptly stop benzodiazepines or barbiturates.** Doing so can precipitate life-threatening withdrawal. Management must involve a **carefully supervised, gradual taper** over days to weeks. **Taper protocols:** 1. **Benzodiazepine taper** (e.g., for someone on lorazepam 4 mg daily): - Week 1: 3.5 mg daily (10% reduction) - Week 2: 3 mg daily - Week 3: 2.5 mg daily - Continue by 10–20% reductions every few days - Total duration: 1–4 weeks, depending on dose and duration of use - Longer tapers (slower) may be needed for very high doses or long-term use 2. **Barbiturate taper** (requires hospitalization, more complex): - Similar principle, but conversion to a long-acting barbiturate (phenobarbital) is often done first to simplify dosing - Reduction by 10–15% every 3 days - Requires inpatient monitoring for withdrawal symptoms 3. **Switching strategies**: - For benzodiazepine withdrawal, some protocols involve converting the short-acting benzodiazepine to a longer-acting equivalent (e.g., alprazolam → diazepam), then tapering the long-acting drug (easier to taper longer-acting drugs) - For barbiturates, conversion to phenobarbital is standard **Nursing considerations during a taper:** - **Assess baseline withdrawal risk**: amount used, duration, previous withdrawal experiences, current psychiatric and medical status - **Establish a seizure precautions environment** if hospitalization is needed - **Monitor vital signs frequently** for signs of emerging withdrawal (tachycardia, hypertension, tremor) - **Educate the patient**: explain the taper plan, the risks of abrupt discontinuation, and the timeline - **Assess for withdrawal symptoms** at each dose adjustment; if withdrawal symptoms emerge, hold the taper temporarily or slow it further - **Provide supportive care**: reassurance, a calm environment, sleep aids (non-benzodiazepine), anxiety support - **Monitor for **seizures**: have emergency seizure equipment available; administer benzodiazepines if seizures occur - **Coordination with provider**: the prescriber must be involved; a coordinated taper plan should be documented **If withdrawal occurs despite a taper:** - **Seizures**: Treat with IV benzodiazepines (lorazepam 2–4 mg IV); place on seizure precautions; may need ICU admission - **Delirium**: Similar management to alcohol withdrawal—safe environment, benzodiazepines, vital sign monitoring, treatment of electrolyte abnormalities - **Autonomic instability**: Support vital signs; consider antihypertensive or antitachycardia medications if severe ### Flumazenil: Benzodiazepine Antagonist (Use with Caution) **Flumazenil** is a competitive antagonist of benzodiazepine receptors. It is used to **reverse benzodiazepine overdose** in acute settings (e.g., after anesthesia or accidental overdose). **Mechanism:** Flumazenil competitively binds to benzodiazepine receptors, displacing benzodiazepines and rapidly reversing their effects (sedation, respiratory depression). **Dosing:** - Initial: 0.1 mg IV over 15–30 seconds - Repeat every 30–60 seconds up to 1 mg total - Onset: 1–3 minutes - Duration: 30–40 minutes (flumazenil is short-acting; re-sedation is possible if the benzodiazepine is long-acting) **Nursing considerations and cautions:** 1. **Use with great caution** in **benzodiazepine-dependent patients**: flumazenil can **precipitate acute withdrawal** (tremors, seizures, anxiety, autonomic hyperactivity) in dependent individuals 2. **High seizure risk**: Flumazenil lowers the seizure threshold and is contraindicated in: - Patients with a history of seizures - Those on chronic benzodiazepine therapy - Those with concurrent alcohol or other CNS depressant intoxication - Those with tricyclic antidepressant overdose (TCA + benzodiazepine + flumazenil = high seizure risk) 3. **Use ONLY for acute benzodiazepine overdose in non-dependent individuals**, not for routine benzodiazepine reversal 4. **Monitor continuously for seizures and re-sedation** after flumazenil administration 5. **Have resuscitation equipment and IV benzodiazepines immediately available** in case seizures occur 6. **Never use flumazenil to treat benzodiazepine-dependent patients** or those in benzodiazepine withdrawal; instead, manage withdrawal with a gradual taper ### Benzodiazepine Dependence in Prescribed Therapy An important clinical reality: Many patients prescribed benzodiazepines for legitimate anxiety or insomnia develop **physical dependence**—not addiction (they are not compulsively seeking the drug or using it to get high), but their brain adapts such that stopping abruptly causes withdrawal. **This is common in older adults** who have been on a benzodiazepine (e.g., diazepam) for years for anxiety or sleep. Abruptly stopping causes rebound anxiety and insomnia, so a taper is necessary. **Patient education:** - Benzodiazepines are effective for short-term anxiety/insomnia but are not recommended for long-term use (>2–4 weeks) due to dependence risk - If long-term therapy is needed, the lowest effective dose should be used - Regular assessment of continued need is important - When discontinuing, a slow taper—not abrupt cessation—is required - Non-pharmacologic alternatives (cognitive-behavioral therapy, meditation, exercise) should be incorporated ### Barbiturate Overdose **Barbiturate overdose is a medical emergency with high mortality.** Unlike benzodiazepine overdose (which can be reversed with flumazenil), **there is no specific antidote for barbiturates.** Management is purely supportive: - **Airway management and mechanical ventilation** (if severe respiratory depression) - **IV fluids and supportive care** - **Continuous cardiac and respiratory monitoring** - **Treatment of hypotension** (fluids, vasopressors) - **Alkaline urine** (some protocols use sodium bicarbonate to alkalinize urine, which increases excretion of long-acting barbiturates like phenobarbital) - **Activated charcoal** if recent oral ingestion (within 1–2 hours) - **Dialysis** (in severe cases, especially with long-acting barbiturates) Mortality from severe barbiturate overdose is 1–3%.

Substance use disorders carry profound social stigma, shame, and moral judgment. Many patients have experienced judgment from healthcare providers, family members, and society. The nursing role is to provide **evidence-based, compassionate, non-judgmental care while maintaining firm boundaries and confronting denial and manipulation.** ### The Therapeutic Nursing Stance **Key principles:** 1. **Firm, consistent, and non-judgmental**: - Set clear limits and boundaries (e.g., "You must take your medications as prescribed"; "I cannot cover up your use") - Enforce consequences consistently - **Never shame or moralize** (e.g., avoid "You're destroying your life," "You're a drug addict," or other pejorative language) - Use respectful language: "You have a substance use disorder" rather than "You're a junkie/drunk/addict" - Recognize the person's inherent dignity despite their illness 2. **Confront denial, rationalization, and minimization without hostility**: - Patients often minimize the severity of use ("I only use on weekends") or rationalize it ("I only drink to cope with stress") - Gently point out the discrepancy between stated use and observable consequences: "You've lost your job and your marriage, yet you say your drinking isn't a problem. Help me understand that." - Do not argue; instead, offer observations and ask questions to promote self-reflection - Avoid accusatory language; use "I notice" statements 3. **Avoid enabling and rescuing behaviors**: - **Enabling** means doing things for the patient that they should do for themselves, or covering up consequences of their use - Examples of enabling: lending money (knowing it will be used for drugs), making excuses to employers, bailing them out of legal trouble, providing housing without conditions - **Rescuing** is similar: taking over responsibilities, preventing natural consequences - These behaviors, though well-intentioned, perpetuate the addiction by removing the motivation to change - **Set boundaries**: "I love you, but I cannot lend you money. If you need help with treatment, I will support you." 4. **Encourage responsibility and self-efficacy**: - Patients must recognize that they have a role in their recovery - Avoid language that suggests helplessness ("You're powerless") or that recovery depends solely on others - Use collaborative language: "What can you do to support your recovery?" - Teach problem-solving and coping skills - Celebrate efforts and successes, no matter how small 5. **Use motivational interviewing techniques**: - **Open-ended questions**: "Tell me about your alcohol use" (rather than "You drink too much, don't you?") - **Affirmations**: Recognize strengths ("You've been sober for 2 weeks; that shows real commitment") - **Reflective listening**: Reflect back what you hear ("So you're worried about losing custody of your kids if you don't get help") - **Summarization**: Periodically summarize discrepancies between goals and current behavior - The goal is to help the patient resolve ambivalence about change, not to convince them ### Managing the Addicted Patient's Behavior **Common behavioral issues and nursing responses:** 1. **Denial** ("I don't have a problem; I can stop anytime"): - Point out evidence gently: "You've had three DUIs, lost your job, and your family has asked you to get help. From my perspective, these are signs that alcohol is causing serious problems." - Avoid power struggles; instead, express concern - Explore the patient's goals and help them see the discrepancy 2. **Rationalization** ("I drink because of stress"): - Validate the stress: "I understand work is stressful. Many people experience stress. What are other ways you could manage it besides drinking?" - Help develop alternative coping strategies 3. **Minimization** ("I only drink a couple of beers a day"): - Gently ask clarifying questions: "A couple of beers, or is it more when you think about it?" - Suggest keeping a log or being more precise - Avoid accusation; seek understanding 4. **Manipulation** ("Just let me use my phone to call my mother; I'll only use it for 5 minutes"): - Set clear, enforceable rules from admission - Be polite but firm: "I understand you want to call your mother. You can use the phone during designated call times between 2 and 3 PM." - Do not make exceptions based on persuasion - Explain the rules as part of the treatment structure 5. **Hostility and verbal abuse**: - Do not take it personally; the hostility is often about the discomfort of withdrawal or the shame of the situation - Remain calm and professional - Set limits: "I want to help you, but I cannot accept being spoken to that way. If you need to vent, I'm here to listen respectfully." - Involve your supervisor or security if safety is threatened 6. **Medication non-adherence** (refusing benzodiazepines, disulfiram, etc.): - Explore reasons: "Tell me what concerns you about this medication" - Provide education about why the medication is important - If the patient refuses, document this and explore whether the patient has decision-making capacity (in withdrawal delirium, capacity is impaired) - Involve the physician and discuss alternatives ### Addressing Codependency and Family Involvement **Codependency** is common in families of substance users. Family members may enable the addict by: - Covering up use ("He had the flu" when he actually was intoxicated) - Providing money or housing without conditions - Minimizing the problem ("It's not that bad") - Taking on the person's responsibilities - Sacrificing their own needs and emotional well-being to manage the addict's behavior **Nursing interventions with families:** 1. **Educate families about addiction** as a disease, not a moral failure or character defect 2. **Teach about codependency and enabling**: - Help family members recognize their enabling behaviors - Explain that enabling perpetuates the addiction - Discuss setting healthy boundaries 3. **Refer to Al-Anon or Nar-Anon**: - **Al-Anon** is a 12-step support group for families and friends of alcoholics - **Nar-Anon** is for families and friends of people with opioid or other drug addictions - These groups help families focus on their own recovery and well-being, not on controlling the addict - They provide peer support and a framework for setting boundaries 4. **Family therapy**: - Includes the patient and family members - Addresses communication, conflict resolution, and rebuilding trust - Helps family members understand their role in recovery 5. **Encourage realistic expectations**: - Recovery is a long process; relapse is common - Family members cannot "fix" the addict; the addict must do their own work - Ongoing support is important, but without enabling ### Aftercare and Relapse Prevention **Discharge planning must address:** 1. **Continuing care**: - Referral to outpatient psychiatric/substance abuse counseling - Medication management (methadone, buprenorphine, naltrexone, acamprosate, disulfiram, etc.) - Scheduled follow-up appointments 2. **12-step and peer support programs**: - **Alcoholics Anonymous (AA)**: founded in 1935, widely available; focuses on abstinence and 12 steps of recovery - **Narcotics Anonymous (NA)**: similar to AA but for all drugs - **SMART Recovery**: alternative to 12-step; focuses on self-empowerment and coping skills - **Crystal Meth Anonymous**: specific to methamphetamine - In the Philippines, these programs are available in major cities; encourage attendance at least weekly 3. **Relapse prevention**: - Identify triggers (people, places, situations associated with use) - Develop a plan to avoid or manage triggers - Teach coping skills: stress management, exercise, meditation, journaling, time with supportive people - Educate about the relapse process (often begins with emotional withdrawal or high-risk situations before actual use) - Discuss the importance of calling a sponsor or treatment provider if urges become strong 4. **Addressing social determinants**: - Help with employment (vocational rehabilitation) - Housing assistance (if needed) - Reconnection with supportive family and friends - Educational opportunities - These social factors significantly impact long-term outcomes 5. **Management of comorbid psychiatric conditions**: - Depression, anxiety, PTSD, and other mental illnesses often co-occur with substance use - Ensure treatment is in place (medications, therapy) - Address suicide risk ### The Nurse's Self-Care and Preventing Burnout Working with substance-using patients can be emotionally demanding. Common stressors: - Hearing repeated stories of trauma, pain, and broken promises - Witnessing manipulation and lying - Feeling hopeless when patients relapse - Moral judgment (despite efforts to be non-judgmental, internalized beliefs can lead to frustration) **Self-care strategies for nurses:** - Recognize your own biases and work to address them (this is ongoing) - Set boundaries between professional and personal concerns - Debrief with colleagues; discuss difficult cases in supervision - Maintain your own health: exercise, sleep, nutrition, mindfulness - Recognize small victories; not every patient will have a perfect recovery, but sustained sobriety in one patient is a major win - Consider attending a workshop or training on trauma-informed care and motivational interviewing to deepen your skills - Seek support from employee assistance programs if burnout becomes severe

**Republic Act 9165**, signed into law in 2002, is the primary **Philippine law governing dangerous drugs**. It represents a shift from purely punitive approaches to one that recognizes drug dependence as a health and social problem requiring treatment and rehabilitation. Understanding RA 9165 is essential for Philippine nursing practice and is testable on the NLE. ### Key Institutions Created by RA 9165 **The Dangerous Drugs Board (DDB):** - The **policy-making and coordinating body** for drug-related activities - Composed of representatives from various government agencies and the private sector - Develops policies, strategies, and programs for drug prevention, treatment, and rehabilitation - Oversees the implementation of the law **The Philippine Drug Enforcement Agency (PDEA):** - The **primary enforcement and operational agency** created by RA 9165 - Responsible for investigation, apprehension, and prosecution of drug offenders - Works with the Philippine National Police (PNP), Bureau of Internal Revenue (BIR), and other agencies - Coordinates with international drug enforcement organizations ### Treatment and Rehabilitation Provisions A groundbreaking aspect of RA 9165 is its recognition of drug-dependent persons as **people needing treatment, not merely criminals**. The law provides for: **Voluntary Submission Program:** - Drug-dependent persons can **voluntarily submit themselves** for treatment without legal consequences (if they do so before being arrested) - The person is referred to a treatment facility by the DDB - Successful completion of the program is recognized and documented - This provision aims to incentivize treatment-seeking **Court-Ordered Rehabilitation:** - If a drug-dependent person is arrested, the court may order **mandatory rehabilitation** instead of (or in addition to) incarceration - The person is referred to a treatment facility certified by the DDB - Completion of the program is considered in sentencing **Treatment Facilities:** - The DDB certifies treatment facilities (government and private) throughout the Philippines - Facilities provide detoxification, rehabilitation, counseling, and vocational training - The Department of Health (DOH) also oversees treatment services ### Confidentiality and Privacy Protections **A critical provision of RA 9165:** **Records of drug-dependent patients undergoing treatment and rehabilitation are confidential.** This means: - Medical records, counseling notes, and other treatment documentation cannot be disclosed to third parties (including law enforcement, employers, or family members) without the patient's written consent - **Exceptions exist**: disclosure is permitted when ordered by a court or when necessary to prevent imminent harm - This confidentiality is essential to protect patients' privacy and encourage treatment-seeking without fear of legal or social consequences **Nursing implications:** - Do not disclose any information about a patient's drug treatment or rehabilitation without explicit, written consent - Understand that this confidentiality is both a legal requirement and an ethical principle - Educate patients about their privacy rights - Be aware that confidentiality is sometimes a barrier to family involvement (family members may not be able to access information even if they are involved in care), so clear communication with the patient about what information can be shared is important ### Dangerous Drugs: Classification and Penalties RA 9165 classifies dangerous drugs into several categories based on their nature and potential for abuse. **Penalties escalate based on the type and quantity of drug and the offense (possession, use, manufacture, sale, trafficking)**. **Key drug categories:** 1. **Schedule I** (highest danger, no accepted medical use): - Heroin, cocaine, methamphetamine, LSD, and other hallucinogens - Possession of small amounts for personal use is a violation (not a felony in some cases) - Manufacture, sale, and trafficking carry severe penalties: 12–20+ years imprisonment and substantial fines 2. **Schedule II** (potential for abuse, some medical uses): - Morphine, codeine, and other natural opioids - Amphetamines (prescription) - Barbiturates (prescription) - Penalties are somewhat less severe than Schedule I but still substantial 3. **Schedule III and IV** (lower abuse potential, accepted medical uses): - Benzodiazepines, acetaminophen with codeine, and other medications with controlled components - Regulated but penalties for unauthorized possession/distribution are less severe **Penalties (general framework; specifics depend on quantity and circumstances):** - **Simple possession** (small amount for personal use): Fine and/or community service (for first offense); imprisonment for subsequent offenses - **Possession with intent to sell**: 12–20 years imprisonment, substantial fines - **Sale or distribution**: 12–20 years imprisonment, substantial fines - **Manufacturing**: 12–20 years imprisonment, substantial fines - **Trafficking** (large quantities, often international): Life imprisonment to death penalty in extreme cases - **Use of drug** (testing positive or admission): Rehabilitation, fine, and/or short-term incarceration ### Mandatory Drug Testing RA 9165 **mandates drug testing** for certain populations: - **Pre-employment screening**: Employers may require drug testing before hiring - **Employees in safety-sensitive positions**: Government and private sector workers in positions where drug impairment poses public safety risk (drivers, security personnel, healthcare workers, pilots, etc.) - **Students**: Some schools conduct random drug testing - **Persons arrested or convicted of drug offenses**: Mandatory testing - **Rehabilitation participants**: Drug testing during treatment **Procedures:** - Testing is conducted at DOH-accredited laboratories - Tests typically screen for the drug and its metabolites - Positive results may be confirmed with a second, more specific test (GC-MS) - Results are documented and maintained confidentially - A positive test result triggers further investigation and, if warranted, rehabilitation or legal consequences ### Nursing's Role in RA 9165 Implementation Nurses participate in drug prevention, screening, treatment, and rehabilitation within the framework of RA 9165: **Prevention:** - Health education in schools, communities, and workplaces about the dangers of drug use - Identification of at-risk populations (youth, individuals with early trauma or mental illness) - Promotion of protective factors (family support, education, mental health services, economic opportunities) **Screening and Assessment:** - Routine substance use screening in all healthcare settings (hospitals, clinics, emergency departments) - Use of validated instruments (CAGE, AUDIT, DAST for initial screening; more detailed assessment for diagnosed substance use) - Assessment of withdrawal risk, medical complications, and psychiatric comorbidities - Documentation of findings in compliance with RA 9165 confidentiality requirements **Treatment and Rehabilitation:** - Administration of medications (benzodiazepines, methadone, buprenorphine, etc.) - Monitoring for withdrawal, adverse effects, and medication compliance - Counseling and education about substance use, recovery, and relapse prevention - Coordination with treatment facilities and rehabilitation centers - Support for voluntary submission and court-ordered rehabilitation programs **Harm Reduction:** - While RA 9165 emphasizes treatment and rehabilitation, harm reduction strategies (needle exchange, naloxone distribution, supervised consumption sites) are increasingly recognized as part of a comprehensive public health approach - Nurses may be involved in naloxone distribution programs and education on overdose prevention **Documentation and Confidentiality:** - Proper documentation of substance use, treatment, and rehabilitation - Protection of patient records in accordance with RA 9165 confidentiality provisions - Understanding that disclosure of treatment information requires written consent ### The Philippines' Drug Crisis and Public Health Response The Philippines has faced a severe methamphetamine epidemic. "Shabu" (methamphetamine hydrochloride) is the most commonly abused illegal drug, particularly among young adults and in urban areas. Contributing factors include: - Geographic location (proximity to drug-manufacturing countries in Southeast Asia) - High demand among youth - Economic factors (methamphetamine is relatively affordable and addictive) - Social disorganization in some communities - Limited access to treatment in rural areas **Public health responses have included:** - Enhanced law enforcement and drug seizures (PDEA operations) - Expansion of treatment and rehabilitation facilities - Community-based prevention programs - Drug education in schools - Naloxone and harm reduction initiatives (expanding but still limited) - Advocacy for treatment-focused approaches (though enforcement-heavy approaches remain prominent) **Challenges:** - Limited treatment capacity; waiting lists are common - Stigma against people with substance use disorders (affects help-seeking) - Limited access to evidence-based medications (methadone and buprenorphine are available in major cities but not universally) - Social and economic factors (poverty, unemployment) that perpetuate drug use - Family separation and disruption due to incarceration ### Ethical and Legal Considerations for Nurses **The tension between public health and criminal justice:** - RA 9165 aims to balance treatment and enforcement - Nurses must recognize the therapeutic value of treatment while understanding the legal framework - Avoid moral judgment; treat all patients with dignity regardless of their legal status **Mandatory reporting requirements:** - While RA 9165 emphasizes confidentiality, there may be situations where disclosure is required by law (e.g., if a court orders disclosure for prosecution) - Understand your facility's policies and local legal requirements - Consult with administrators or legal counsel if uncertain **Supporting recovery within the legal framework:** - Even when patients are court-ordered to treatment, the nursing approach should be supportive and therapeutic - Recognize that court-ordered treatment can be as effective as voluntary treatment if the nursing care is compassionate and evidence-based - Focus on the patient's recovery, not on their legal culpability